Company news
Intensity Therapeutics, Inc. news in 2026
Intensity Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
November 5, 2026
Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026
October 30, 2026
Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting
October 23, 2026
Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO...
October 23, 2026
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
August 4, 2026
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
July 15, 2026
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
April 15, 2026
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
March 26, 2026
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
March 23, 2026
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
March 11, 2026
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
March 5, 2026
Intensity Therapeutics Announces Reverse Stock Split
February 13, 2026
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
January 13, 2026